Debt reduction from asset monetization
Expected: Q4 FY26MEDIUM confidence
₹275.52 crores from land/building disposal to improve D/E ratio by Q4 FY26
“Q3 FY26 exceptional gain of ₹275.52 crores from property sale”
Unichem Laboratories Ltd: Is It a Deep Value Opportunity?
AverageAccelerating
As of Mar 28, 2026, Unichem Laboratories Ltd (Pharma - Others) has a deep value score of 57/100 (rated Average). Earnings are accelerating. 1Y return vs Nifty 500: -58%.
PE: Cycle BottomStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💰Trading 61% below estimated fair value — significant discount
Re-Rating Catalysts
1. Debt reduction from asset monetization
Q4 FY26MEDIUM
2. USFDA audit resolution
Q1 FY27LOW
3. Margin recovery to 12-14% OPM
Q4 FY26MEDIUM
Value Trap Risks
1. Working capital trap
HIGH2. Structural industry decline
MEDIUMKey Numbers
PAT Growth YoY
+355%
Stable
Revenue YoY
-2%
Inflection Down
Operating Margin
9.0%
-700 bps YoY
PE Ratio
19.0
PEG Ratio
0.13
Current Price
₹284
3Y PAT CAGR
+61%
Market Cap
2.0K Cr
Valuation
Significantly UndervaluedIs Unichem Laboratories Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Asset monetization and governance improvements could catalyze margin recovery and debt reduction if core business stabilizes.
Verdict
WAIT_FOR_CONFIRMATION
What Could Re-Rate Unichem Laboratories Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
USFDA audit resolution
Expected: Q1 FY27LOW confidence
Expected within 2 quarters to restore export market confidence and pricing power
“USFDA audit mentioned in industry reports as ongoing concern”
Margin recovery to 12-14% OPM
Expected: Q4 FY26MEDIUM confidence
Through cost optimization initiatives already underway
“Sequential OPM improvement from 4.27% in Q1 to 8.59% in Q3 FY26”
What Are the Value Trap Risks for Unichem Laboratories Ltd?
Risks that could prevent re-rating or deepen the value trap
Working capital trap
HIGHContinued inventory build-up or receivables collection issues
Impact: -500 bps margin impact
Management view: Company is addressing through working capital optimization initiatives
Monitor: CFO to Revenue ratio
Structural industry decline
MEDIUMFurther price erosion in key markets
Impact: -300 bps margin impact
Management view: Company focusing on niche products and export markets
Monitor: Export revenue growth rate
What Is Unichem Laboratories Ltd's Management Guidance?
Forward-looking targets from management for FY27
Management Tone: CAUTIOUS
Key Milestones
• USFDA audit resolution
• Debt reduction completion
• Margin recovery to 12-14%
How Fast Is Unichem Laboratories Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -2% | +18% | Inflection Down |
| PAT (Net Profit) | +355% | +61% | Stable |
| OPM | 9.0% | -700 bps | Volatile |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Other Deep Value Stocks in Pharma - Others
Frequently Asked Questions: Unichem Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Unichem Laboratories Ltd's deep value score?
Unichem Laboratories Ltd has a deep value score of 57/100 (rated Average). This score is calculated from three components
- Earnings Score: 33/40 — measures PAT growth momentum across quarters
- Underperformance Score: 32/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
- Quality Score: 19/25 — operational quality (margins, revenue growth, valuation)
Is Unichem Laboratories Ltd fundamentally improving?
Unichem Laboratories Ltd's quarterly profit (PAT) growth trajectory
- Latest Quarter PAT Growth (QoQ): +500%
- Previous Quarter PAT Growth (QoQ): -14%
- 2 Quarters Ago PAT Growth (QoQ): -120%
- PAT Acceleration: +309.9pp (profits are accelerating)
- 1 consecutive quarters of positive PAT growth
Why is Unichem Laboratories Ltd underperforming despite good earnings?
Unichem Laboratories Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
- 1-Year Return vs Nifty 500: -58%
- 6-Month Return vs Nifty 500: -33%
- 3-Month Return vs Nifty 500: -25%
- Yet average quarterly PAT growth is +122% — earnings are improving
- The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.
What is the earnings momentum for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's earnings momentum is Accelerating — profit growth is speeding up.
- PAT QoQ progression: -120% → -14% → +500% (2Q ago → 1Q ago → latest)
- Acceleration: +309.9pp
- PAT YoY Growth: +355%
Is Unichem Laboratories Ltd undervalued?
Unichem Laboratories Ltd's valuation metrics
- Price-to-Earnings (PE): 6.8x
- Price-to-Book (PB): 0.8x
- PEG Ratio: 0.1x
- Margin of Safety: +61% (appears undervalued)
What are the revenue and margin trends for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's revenue and margin trends
- Latest Quarter Revenue Growth (QoQ): -10%
- Average Quarterly Revenue Growth: -3%
- Revenue Acceleration: +0.2pp
- Latest OPM Change: -2.8pp (margins contracting)
- Average OPM Change: -1.9pp
- Revenue YoY: -2%
What is Unichem Laboratories Ltd's trailing twelve month (TTM) performance?
Unichem Laboratories Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹295 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +13.3% YoY
- TTM Operating Margin: 9.7%
What sector does Unichem Laboratories Ltd belong to?
Unichem Laboratories Ltd key facts
- Sector: Pharma - Others
- Market Cap: ₹2.0K Cr
- Rank in Pharma - Others: #1 by value score
- Overall rank among all deep value stocks: #3
Is Unichem Laboratories Ltd a good deep value opportunity to study?
Unichem Laboratories Ltd shows limited deep value signals currently — score is 57/100 (Average). Monitor for improvement.
- Value Score: 57/100 (Average)
- Earnings: Accelerating
- 1Y Underperformance: -58% vs Nifty 500
What is the bull and bear case for Unichem Laboratories Ltd?
Research Signals (Bull Case)
- Earnings accelerating — profit growth speeding up
- Appears undervalued based on fair value analysis
- Revenue growth also accelerating
Risk Factors (Bear Case)
- Significant underperformance (-58% vs Nifty 1Y)
- Margin pressure warning
- Operating margins contracting
Which other Pharma - Others stocks are deep value opportunities?
Other deep value stocks in Pharma - Others
- Remus Pharmaceuticals Ltd — Score 53/100, Average, earnings accelerating
- Syncom Formulations (India) Ltd — Score 53/100, Average, earnings accelerating
How does the Pharma - Others sector look for deep value?
Pharma - Others deep value sector overview
- 3 deep value stocks in this sector
- Average value score: 54/100
- Avg PAT acceleration: +108.5pp
- Top pick: Unichem Laboratories Ltd
What is deep value investing?
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
How is the deep value score calculated?
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
What are the growth catalysts for Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 3 key growth catalysts identified from recent earnings analysis
- Debt reduction from asset monetization
- USFDA audit resolution
- Margin recovery to 12-14% OPM
What are the key risks in Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 2 key risks worth monitoring
- Working capital trap
- Structural industry decline
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.